TRACON Pharmaceuticals (TCON)
(Delayed Data from OTC)
$0.18 USD
-0.03 (-15.66%)
Updated Sep 20, 2024 03:30 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 41 - 60 ( 72 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Partner Data for Envafolimab Bodes Well for U.S. Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Highlights from H.C. Wainwright Conference Presentation; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Protocol of the Pivotal ENVASARC Trial for Envafolimab in Sarcoma Receives Clearance From the FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Pivotal ENVASARC Trial IND Filed With FDA; First Patient Expected to Enroll 4Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Protocol Filing With the FDA for ENVASARC Pivotal Trial Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Envafolimab Pivotal Trial Anticipated to Start 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
TRACON Retains Global Rights to TRC253 Following Disappointing Data; Lowering PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
May 8 Teleconference With FDA to Discuss ENVASARC Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Request for Type B FDA Meeting Regarding Envafolimab Pivotal Study Submitted
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Development of DE-122 Discontinued; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Results; Envafolimab Pivotal Study in 2H20; Lowering PT Due to Recent Capital Raises
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Potentially Transformational Deal Announced; Raising PT by $3 to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updating Model and Price Target After 1-for-10 Reverse Stock Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; DE-122 Data in Wet AMD Expected 1H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Partnering to Success; Initiating Coverage With a Buy and $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E